title: Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation.
abstract: In immunocompetent patients, specific human leukocyte antigen (HLA) class II alleles have been associated with the severity of hepatitis C virus (HCV)-related disease, in particular, HLA-DRB1*11 has been found to exert a protective effect. The authors have analyzed the role of HLA class I and II alleles in determining the frequency, timing, and progression of histologically proven recurrent hepatitis C in 89 patients who underwent a liver transplant for HCV-related cirrhosis. In addition, the influence of HLA mismatch between donor and recipient, HCV genotype, and use of steroid pulses was also evaluated. Median patient follow up was 35 months (range 4-119). HLA-DRB1 typing was performed by genomic analysis in all cases. Liver biopsies were obtained routinely and at least at yearly intervals. Histologically proven recurrent hepatitis was observed in 46 patients (52%), 10 patients progressing to stage 5-6 fibrosis in most cases within 2 years after transplant. By univariate analysis, 3 variables, HLA-B14, HLA-DRB1*04, and HLA-DRB1 donor/recipient mismatch, showed a significant effect on time to recurrent hepatitis C disease. These parameters were included in a multivariate regression model along with HCV genotype, treatment with steroid pulses and DRB1*11. HLA-B14, HLA-DRB1*04, and HLA-DRB1 donor/recipient mismatch were confirmed to provide a significant and independent contribution to the risk of hepatitic disease recurrence. As for the severity of the disease, none of the 10 patients with stage 5-6 hepatitis carried the HLA-DRB1*11 allele, in line with what was observed in nontransplant subjects. Our results suggest that in posttransplant recurrent hepatitis C, immunogenetic factors are relevant in determining HCV infection outcome.
authors.affiliation: Department of Gastroenterology, Ospedale San Giuseppe, Milano, Italy. lsbelli@tin.it
authors.forename: L S
authors.initials: LS
authors.lastname: Belli
authors.forename: C
authors.initials: C
authors.lastname: Zavaglia
authors.forename: A B
authors.initials: AB
authors.lastname: Alberti
authors.forename: F
authors.initials: F
authors.lastname: Poli
authors.forename: G
authors.initials: G
authors.lastname: Rondinara
authors.forename: E
authors.initials: E
authors.lastname: Silini
authors.forename: E
authors.initials: E
authors.lastname: Taioli
authors.forename: L
authors.initials: L
authors.lastname: de Carlis
authors.forename: M
authors.initials: M
authors.lastname: Scalamogna
authors.forename: D
authors.initials: D
authors.lastname: Forti
authors.forename: G
authors.initials: G
authors.lastname: Pinzello
authors.forename: G
authors.initials: G
authors.lastname: Idèo
mesh_terms: D000328:Adult; D000483:Alleles; D018450:Disease Progression; D005260:Female; D005787:Gene Frequency; D006526:Hepatitis C / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology* / Q000503:physiopathology; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D000949:Histocompatibility Antigens Class II / Q000235:genetics; D006801:Humans; D007125:Immunogenetics; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011183:Postoperative Complications; D012008:Recurrence
chemical_list: D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II